Pathogenesis of Thrombotic Microangiopathy

血栓性微血管病的发病机制

• 批准号: 9139498
• 负责人: X. Long Zheng
• 金额: $ 45.54万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-14 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9139498
• 关键词: Adhesives; Affect; Age; Amino Acids; Antibodies; Binding; Binding Sites; Biological Assay; Biological Process; Blood Circulation; Blood Coagulation Disorders; Blood capillaries; C-terminal; Cleaved cell; Clinical; Code; Complement; Complement 3b; Complement Activation; Complement Factor H; Coupled; Data; Defect; Deuterium; Development; Disease; Disease Progression; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Event; F8 gene; Factor VIII; Fibrinogen; Genes; Genetic; Genetic Polymorphism; Health; Hemolytic-Uremic Syndrome; Hemostatic function; Histology; Human; Hydrogen; Immunohistochemistry; Inherited; Investigation; Kinetics; Laboratories; Lead; Light; Liquid substance; Mass Spectrum Analysis; Mediating; Metalloproteases; Monoclonal Antibodies; Mus; Mutate; Mutation; Organ; Outcome; Pathogenesis; Pathology; Patients; Physiological; Plasma; Platelet Glycoproteins; Positioning Attribute; Predisposition; Prevalence; Prevention; Process; Proteolysis; Proteolytic Processing; Reaction; Recombinants; Recovery; Regulation; Resolution; Role; Serine Protease; Syndrome; Testing; Thrombosis; Thrombotic Thrombocytopenic Purpura; Thrombus; Titrations; Transgenic Mice; Uncertainty; Wild Type Mouse; arteriole; capillary; clinical phenotype; efficacy testing; experience; in vivo; inhibitor/antagonist; mouse model; mutant; novel therapeutics; prevent; sex; shear stress; tool; von Willebrand Disease; von Willebrand Factor

 DESCRIPTION (provided by applicant): Deficiency of plasma ADAMTS13 activity, either hereditary or acquired, causes thrombotic thrombocytopenic purpura (TTP). However, the triggering events and mechanisms underlying the pathogenesis of TTP are not fully understood. Emerging data suggest that complement activation may be associated with both hemolytic uremic syndrome (HUS) and TTP. In Aim 1, we propose to determine the effects of CFH on ADAMTS13- mediated VWF proteolysis and its adhesive function under flow. We will also determine the kinetics and mechanism of such interactions and how such an interaction affects complement activation/inactivation. In Aim 2, we will determine the role of genetic or acquired deficiency of CFH on the occurrence, progression, and outcome of acquired TTP (with inhibitors) in murine models. In Aim 3, we propose to determine the prevalence of mutations in genes in complement components and regulators in patients with acquired TTP patients with inhibitors. We pursue the hypothesis that by inhibiting complement activation with anti-complement therapy either alone or in combination with rADAMTS13 one can better prevent the onset and progression of the disease pathology or accelerate its recovery. The results of the proposed study will advance our understanding of the fundamental role of CFH in regulation of VWF function under physiological shear stress, shed new light on the mechanisms of acquired TTP, and provide invaluable tools for testing the efficacy of novel therapeutics.

 描述（由申请方提供）：遗传性或获得性血浆ADAMTS 13活性缺乏可导致血栓性血小板减少性紫癜（TTP）。然而，TTP发病机制的触发事件和机制尚未完全了解。新出现的数据表明，补体激活可能与溶血性尿毒综合征（HUS）和TTP。在目的1中，我们建议确定CFH对ADAMTS 13介导的VWF蛋白水解及其在流动下的粘附功能的影响。我们还将确定这种相互作用的动力学和机制，以及这种相互作用如何影响补体激活/失活。在目标2中，我们将确定遗传性或获得性CFH缺陷在小鼠模型中获得性TTP（含抑制剂）的发生、进展和结局中的作用。在目标3中，我们建议确定获得性TTP患者补体成分和调节因子基因突变的患病率。我们追求的假设是，通过单独或与rADAMTS 13组合的抗补体疗法抑制补体激活，可以更好地预防疾病病理的发生和进展或加速其恢复。这项研究的结果将促进我们对CFH在生理剪切应力下调节VWF功能的基本作用的理解，为获得性TTP的机制提供新的认识，并为测试新疗法的疗效提供宝贵的工具。